ArticleAdvances in therapy2021

Cost-Effectiveness Analysis of Cemiplimab Versus Chemotherapy as First-Line Treatment in Advanced NSCLC with PD-L1 Expression Levels of at Least 50.

Liting Wang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.